γ-Secretase in Alzheimer's disease
1Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. hurj@mskcc.org.
Experimental & Molecular Medicine
|April 9, 2022
Summary
Alzheimer's disease involves brain cell loss and amyloid plaques. Targeting gamma-secretase, crucial for amyloid-beta production, is key, but requires specific modulators to avoid side effects.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) is characterized by synaptic and neuronal loss, with amyloid plaques (Aβ) as a hallmark.
- Aβ is generated through sequential cleavage of amyloid precursor protein (APP) by β-secretase and γ-secretase.
- γ-Secretase's role in Aβ production makes it a therapeutic target for AD.
Purpose of the Study:
- To review decades of research on γ-secretase in Alzheimer's disease.
- To discuss the challenges and advancements in targeting γ-secretase for AD treatment.
- To highlight the importance of understanding γ-secretase modulators (GSMs) and their binding sites.
Main Methods:
- Review of existing literature on γ-secretase, its substrates, and inhibitors/modulators.
- Analysis of the role of γ-secretase in APP processing and Aβ generation.
- Examination of the mechanisms and clinical implications of γ-secretase inhibitors (GSIs) and modulators (GSMs).
Main Results:
- γ-Secretase inhibitors (GSIs) have shown side effects due to off-target inhibition of substrates like Notch.
- γ-Secretase modulators (GSMs) offer a more specific approach to regulating γ-secretase activity.
- Identifying binding sites and transiently interacting proteins is crucial for developing effective GSMs.
Conclusions:
- Modulating γ-secretase activity, rather than inhibiting it, is a promising strategy for AD treatment.
- Further research into the specific binding sites and regulatory proteins of γ-secretase is essential.
- Developing selective GSMs could overcome the limitations of GSIs and offer a safer therapeutic avenue for AD.
Related Concept Videos
01:26Alzheimer's Disease: Overview
705
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
705
01:22Alzheimer's Disease: Treatment
274
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
274
03:03Amyloid Fibrils
10.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.2K